Cleavage of Endoplasmic Reticulum Proteins in Hepatocellular Carcinoma: Detection of Generated Fragments in Patient Sera

Gastroenterology

Volumn 130, Issue 7, 2006, Pages 2010-2022

  Chignard, Nicolas ^a   Shang, Sufen ^b   Wang, Hong ^b   Marrero, Jorge ^a   Bréchot, Christian ^c   Hanash, Samir ^b   Beretta, Laura ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; GLUCOSE REGULATED PROTEIN 78; MESSENGER RNA; MOLECULAR MARKER; PROTEIN DISULFIDE ISOMERASE;

ARTICLE; CALRETICULIN GENE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CHRONIC HEPATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOPLASMIC RETICULUM; GENE; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DISULFIDE ISOMERASE A3 GENE; PROTEIN DISULFIDE ISOMERASE GENE; PROTEOMICS; STATISTICAL SIGNIFICANCE; SUPERNATANT;

EID: 33744526790     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.02.058     Document Type: Article

References (43)

1. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer. worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
2. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
3. El-Serag H.B., Mason A.C., and Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33 (2001) 62-65
4. El-Serag H.B. Hepatocellular carcinoma. recent trends in the United States. Gastroenterology 127 (2004) S27-S34
5. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., Christensen E., Pagliaro L., Colombo M., and Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
6. Di Bisceglie A.M. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127 (2004) S104-S107
7. Daniele B., Bencivenga A., Megna A.S., and Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127 (2004) S108-S112
8. Hong W.S., and Hong S.I. Clinical usefulness of α-1-antitrypsin in the diagnosis of hepatocellular carcinoma. J Korean Med Sci 6 (1991) 206-213
9. Marrero J.A., Su G.L., Wei W., Emick D., Conjeevaram H.S., Fontana R.J., and Lok A.S. Des-γ carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37 (2003) 1114-1121
10. Mita Y., Aoyagi Y., Yanagi M., Suda T., Suzuki Y., and Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82 (1998) 1643-1648
11. Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E., and Filmus J. Glypican-3. a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125 (2003) 89-97
12. Yao D.F., Huang Z.W., Chen S.Z., Huang J.F., Lu J.X., Xiao M.B., and Meng X.Y. Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specific bands of serum γ-glutamyltransferase. Am J Clin Pathol 110 (1998) 743-749
13. Cui R., He J., Zhang F., Wang B., Ding H., Shen H., Li Y., and Chen X. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetoprotein. Br J Cancer 88 (2003) 1878-1882
14. Chignard N., and Beretta L. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology 127 (2004) S120-S125
15. Kuick R.D., Skolnick M.M., Hanash S.M., and Neel J.V. A two-dimensional electrophoresis-related laboratory information processing system. spot matching. Electrophoresis 12 (1991) 736-746
16. Asakawa J., Kuick R., Neel J.V., Kodaira M., Satoh C., and Hanash S.M. Genetic variation detected by quantitative analysis of end-labeled genomic DNA fragments. Proc Natl Acad Sci U S A 91 (1994) 9052-9056
17. Le Naour F., Brichory F., Misek D.E., Brechot C., Hanash S.M., and Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 1 (2002) 197-203
18. Kim W., Oe Lim S., Kim J.S., Ryu Y.H., Byeon J.Y., Kim H.J., Kim Y.I., Heo J.S., Park Y.M., and Jung G. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res 9 (2003) 5493-5500
19. Lim S.O., Park S.J., Kim W., Park S.G., Kim H.J., Kim Y.I., Sohn T.S., Noh J.H., and Jung G. Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 291 (2002) 1031-1037
20. Takashima M., Kuramitsu Y., Yokoyama Y., Iizuka N., Toda T., Sakaida I., Okita K., Oka M., and Nakamura K. Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics 3 (2003) 2487-2493
21. Park K.S., Kim H., Kim N.G., Cho S.Y., Choi K.H., Seong J.K., and Paik Y.K. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology 35 (2002) 1459-1466
22. Anderson N.L., Polanski M., Pieper R., Gatlin T., Tirumalai R.S., Conrads T.P., Veenstra T.D., Adkins J.N., Pounds J.G., Fagan R., and Lobley A. The human plasma proteome. a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3 (2004) 311-326
23. Park K.S., Cho S.Y., Kim H., and Paik Y.K. Proteomic alterations of the variants of human aldehyde dehydrogenase isozymes correlate with hepatocellular carcinoma. Int J Cancer 97 (2002) 261-265
24. Zeindl-Eberhart E., Haraida S., Liebmann S., Jungblut P.R., Lamer S., Mayer D., Jager G., Chung S., and Rabes H.M. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology 39 (2004) 540-549
25. Kleizen B., and Braakman I. Protein folding and quality control in the endoplasmic reticulum. Curr Opin Cell Biol 16 (2004) 343-349
26. Ellgaard L., and Frickel E.M. Calnexin, calreticulin, and ERp57. teammates in glycoprotein folding. Cell Biochem Biophys 39 (2003) 223-247
27. 2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 37 (2005) 260-266
28. Dhahbi J.M., Cao S.X., Tillman J.B., Mote P.L., Madore M., Walford R.L., and Spindler S.R. Chaperone-mediated regulation of hepatic protein secretion by caloric restriction. Biochem Biophys Res Commun 284 (2001) 335-339
29. Wang L., Fast D.G., and Attie A.D. The enzymatic and non-enzymatic roles of protein-disulfide isomerase in apolipoprotein B secretion. J Biol Chem 272 (1997) 27644-27651
30. Dorner A.J., Wasley L.C., and Kaufman R.J. Overexpression of GRP78 mitigates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells. EMBO J 11 (1992) 1563-1571
31. Dorner A.J., Krane M.G., and Kaufman R.J. Reduction of endogenous GRP78 levels improves secretion of a heterologous protein in CHO cells. Mol Cell Biol 8 (1988) 4063-4070
32. Paulsson K., and Wang P. Chaperones and folding of MHC class I molecules in the endoplasmic reticulum. Biochim Biophys Acta 1641 (2003) 1-12
33. Marincola F.M., Jaffee E.M., Hicklin D.J., and Ferrone S. Escape of human solid tumors from T-cell recognition. molecular mechanisms and functional significance. Adv Immunol 74 (2000) 181-273
34. Chang C.C., Campoli M., and Ferrone S. HLA class I antigen expression in malignant cells. why does it not always correlate with CTL-mediated lysis?. Curr Opin Immunol 16 (2004) 644-650
35. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 21 (2000) 455-464
36. Seliger B., Atkins D., Bock M., Ritz U., Ferrone S., Huber C., and Storkel S. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 9 (2003) 1721-1727
37. Seliger B., Ritz U., Abele R., Bock M., Tampe R., Sutter G., Drexler I., Huber C., and Ferrone S. Immune escape of melanoma. first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61 (2001) 8647-8650
38. Seliger B., Wollscheid U., Momburg F., Blankenstein T., and Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 61 (2001) 1095-1099
39. Garcia-Lora A., Martinez M., Algarra I., Gaforio J.J., and Garrido F. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated down-regulation of APM components. Int J Cancer 106 (2003) 521-527
40. Ogino T., Bandoh N., Hayashi T., Miyokawa N., Harabuchi Y., and Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 9 (2003) 4043-4051
41. Dissemond J., Busch M., Kothen T., Mors J., Weimann T.K., Lindeke A., Goos M., and Wagner S.N. Differential down-regulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. Cancer Lett 203 (2004) 225-231
42. Hippo Y., Watanabe K., Watanabe A., Midorikawa Y., Yamamoto S., Ihara S., Tokita S., Iwanari H., Ito Y., Nakano K., Nezu J., Tsunoda H., Yoshino T., Ohizumi I., Tsuchiya M., Ohnishi S., Makuuchi M., Hamakubo T., Kodama T., and Aburatani H. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64 (2004) 2418-2423
43. Paradis V., Degos F., Dargere D., Pham N., Belghiti J., Degott C., Janeau J.L., Bezeaud A., Delforge D., Cubizolles M., Laurendeau I., and Bedossa P. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41 (2004) 40-47